CPWM
GILD icon

Cypress Point Wealth Management’s Gilead Sciences GILD Stock Holding History

Cypress Point Wealth Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,450
Closed -$202K – 149
2026
Q1 		$202K Buy
+1,450
New +$203K 0.04% 117
2021
Q3 		– Sell
-225
Closed -$15K – 176
2021
Q2 		$15K Buy
+225
New +$15K 0.01% 118

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cypress Point Wealth Management's GILD Position: Q2 2026 in Review

Cypress Point Wealth Management sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 1,450 shares — an estimated $202K sold.

Cypress Point Wealth Management first reported a position in GILD in Q2 2021 and held it in 2 quarters. The position peaked at $202K in Q1 2026. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Cypress Point Wealth Management reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
  • Cypress Point Wealth Management sold 1,450 Gilead Sciences shares in Q2 2026, an estimated $202K.
  • Cypress Point Wealth Management first reported a position in Gilead Sciences in Q2 2021 and held it in 2 quarters.
  • Cypress Point Wealth Management's Gilead Sciences position peaked at $202K in Q1 2026.
  • 2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Cypress Point Wealth Management's 13F filing for Q2 2026, filed 17 Jul 2026.